written on 18.06.2014

Could Actelion and Cipla be next on Big Pharma's M&A takeover list?


Switzerland's Actelion has been on a winning streak of late, charting better-than-expected clinical trial results and beating analysts' earnings expectations thanks to fast-growing sales of its new blood pressure treatment. It's no wonder, then, that the company is a perennial subject of takeover rumors. But CEO Jean-Paul Clozel isn't interested in entertaining any deal offers.